Evidence map›Paper›PMID 37957680›Full record

ArticleTrials2023

SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.

Jennifer G McIntosh, Jon D Emery, Anna Wood, Patty Chondros, Belinda C Goodwin, Judy Trevena, Carlene Wilson, Shanton Chang, Jane Hocking, Tina Campbell and 16 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 2 countries.

Jennifer G McIntoshCentre for Cancer Research, University of Melbourne, Parkville, Australia. jennifer.mcintosh@unimelb.edu.au.ORCID http://orcid.org/0000-0002-6655-0940
Jon D EmeryCentre for Cancer Research, University of Melbourne, Parkville, Australia.
Anna WoodCentre for Cancer Research, University of Melbourne, Parkville, Australia.
Patty ChondrosDepartment of General Practice and Primary Care, University of Melbourne, Parkville, Australia.
Belinda C GoodwinCentre for Epidemiology and Biostatistics, University of Melbourne Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Judy TrevenaDepartment of General Practice and Primary Care, University of Melbourne, Parkville, Australia.
Carlene WilsonCentre for Epidemiology and Biostatistics, University of Melbourne Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Shanton ChangSchool of Computing and Information Systems, The University of Melbourne, Parkville, Australia.
Jane HockingCentre for Epidemiology and Biostatistics, University of Melbourne Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Tina CampbellHealthily Pty Ltd, Melbourne, Australia.
Finlay MacraeColorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, Australia.
Kristi MilleyCentre for Cancer Research, University of Melbourne, Parkville, Australia.
Jie-Bin LewThe Daffodil Centre, a joint venture between Cancer Council NSW and the University of Sydney, Sydney, Australia.
Claire NightingaleCentre for Epidemiology and Biostatistics, University of Melbourne Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Ian Dixon, Consumer Representative, Melbourne, Australia.
Makala Castelli, Consumer Representative, Melbourne, Australia.
Nicholas Lee, Consumer Representative, Melbourne, Australia.
Lyle InnesHealthily Pty Ltd, Melbourne, Australia.
Tamara JolleyCancer Council Queensland, Fortitude Valley, QLD, Australia.
Sabine FletcherCancer Council Queensland, Fortitude Valley, QLD, Australia.
Lyn BuchananCentre for Epidemiology and Biostatistics, University of Melbourne Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Sally DoncovioVictorian Department of Health, Melbourne, Australia.
Kate BrounCancer Council Victoria, Melbourne, Australia.
Glenn AustinQueensland Health, Brisbane, Australia.
Joyce JiangCentre for Epidemiology and Biostatistics, University of Melbourne Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Mark A JenkinsCentre for Cancer Research, University of Melbourne, Parkville, Australia.
The University of Melbourne · AUHouse of Representatives · NLCancer Council Queensland · AUCancer Council Victoria · AUGovernment of Western Australia Department of Health · AUQueensland Health · AUThe Royal Melbourne Hospital · AUThe University of Sydney · AU

Funding

National Health and Medical Research Council ID2014703
6 · The paper itself

Abstract

backgroundAustralia persistently has one of the highest rates of colorectal cancer (CRC) in the world. Australia's National Bowel Cancer Screening Program (NBCSP) sends a biennial Faecal Immunochemical Test (FIT)-the 'NBCSP kit'-to everyone eligible for the programme between 50 and 74 years old; however, participation in the programme is low, especially in the 50- to 60-year-old age group. Our previous efficacy trial ('SMARTscreen') demonstrated an absolute increase in uptake of 16.5% (95% confidence interval = 2.02-30.9%) for people sent an SMS with motivational and instructional videos, from their general practice prior to receiving their NBCSP kit, compared to those receiving usual care. Building on the strengths of the SMARTscreen trial and addressing limitations, the 'SMARTERscreen' trial will test the effect on participation in the NBCSP of sending either an SMS only or an SMS with online video material to general practice patients due to receive their NBCSP compared to 'usual care'.

methodsSMARTERscreen is a three-arm stratified cluster randomised controlled trial involving 63 general practices in two states in Australia. Eligible patients are patients who are aged 49-60 years and due to receive their NBCSP kit within the next 2 weeks during the intervention period. General practices will be equally randomised to three trial arms (21:21:21, estimated average 260 patients/practice). The two interventions include (i) an SMS with an encouraging message from their general practice or (ii) the same SMS with weblinks to additional motivational and instructional videos. The control arm will receive 'usual care'. Using the intention-to-treat approach, primary analysis will estimate the three pair-wise between-arm differences in the proportion of eligible patients who participate in the NBCSP within 6 months of when their kit is sent, utilising screening data from the Australian National Cancer Screening Register (NCSR). Patient intervention adherence to the interventions will also be evaluated. Findings will be incorporated into the Policy1-Bowel microsimulation model to estimate the long-term health benefits and cost-effectiveness of the interventions. DISCUSSION: SMARTERscreen will provide high-level evidence determining whether an SMS or an SMS with web-based material sent to general practice patients prior to receiving their NBCSP kit increases participation in bowel cancer screening.

trial registrationAustralian New Zealand Clinical Trials Registry ACTRN12623000036617. Registered on 13 January 2023. Trial URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385119&isClinicalTrial=False.

Indexed as

Colorectal NeoplasmsGeneral PracticeAgedAustraliaEarly Detection of CancerHumansIntestinesMass ScreeningMiddle AgedRandomized Controlled Trials as TopicAustralian National Bowel Cancer Screening ProgramBehaviour changeColorectal cancer screeningGeneral practice

Identifiers

PMID37957680
PMCPMC10642038
OpenAlexW4388635014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.